Interim Results of MATCH Study Demonstrate Improved Decision Making and Clinical Outcomes When Using Mind.Px™ to Determine Biologic Drug Class for Psoriasis Patients
October 20, 2022 08:00 ET
|
Mindera Health
San Diego, CA, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Interim clinical utility and patient outcomes data regarding Mindera Health’s Mind.Px™ test from the ongoing MATCH study were recently presented at...
Mindera Health™ Launches Pilot with National Health Insurance Company to Improve Management of Moderate-To-Severe Psoriasis Patients Through Precision Medicine
April 28, 2022 08:00 ET
|
Mindera Health
San Diego, CA, April 28, 2022 (GLOBE NEWSWIRE) -- Mindera Health™, the developer of the groundbreaking Dermal Intelligence™ platform - the first realization of precision medicine in psoriasis, has...
Mindera Health™ Appoints Ted St. Martin as Chief Financial Officer
March 10, 2022 08:00 ET
|
Mindera Health
San Diego, CA, March 10, 2022 (GLOBE NEWSWIRE) -- Mindera Health™, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of precision medicine in psoriasis, ...
Mindera Health™ Appoints Deborah L. Rice-Johnson to its Board of Directors
March 01, 2022 08:00 ET
|
Mindera Health
San Diego, CA, March 01, 2022 (GLOBE NEWSWIRE) -- Mindera Health™, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in...
Mindera Health™ and WellDyne announce a definitive agreement to improve management of moderate-to-severe psoriasis patients
January 04, 2022 11:00 ET
|
Mindera Health
SAN DIEGO, CA and LAKELAND, FL, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Mindera Health™ and WellDyne have entered into a definitive agreement to improve the management of psoriasis patients with moderate...
Mindera Health™ announces publication of positive results from STAMP-1 and STAMP-2 studies
November 16, 2021 11:30 ET
|
Mindera Health
San Diego, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Mindera Health™, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in psoriasis,...
Mindera Health™ announces first patient enrolled in the MATCH Study: a clinical utility evaluation of the impact of Mind.Px™ on response rates of psoriasis patients who are prescribed biologics
October 21, 2021 12:00 ET
|
Mindera Health
San Diego, CA, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Mindera Health, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in psoriasis,...